David Itskoviz1, Doron Boltin2, Haim Leibovitzh2, Tsachi Tsadok Perets2, Doron Comaneshter3, Arnon Cohen3, Yaron Niv2, Zohar Levi2. 1. Department of Gastroenterology, Rabin Medical Center, Beilinson Campus and the Sackler Faculty of Medicine, Tel Aviv University, Israel. Electronic address: mditskov@gmail.com. 2. Department of Gastroenterology, Rabin Medical Center, Beilinson Campus and the Sackler Faculty of Medicine, Tel Aviv University, Israel. 3. The Department of Quality Measures and Research, Chief Physician Office, Clalit Health Services, Israel.
Abstract
BACKGROUND AND AIMS: Data regarding the impact of smoking on the success of Helicobacter pylori (H. pylori) eradication are conflicting, partially due to the fact that sociodemographic status is associated with both smoking and H. pylori treatment success. We aimed to assess the effect of smoking on H. pylori eradication rates after controlling for sociodemographic confounders. METHODS: Included were subjects aged 15 years or older, with a first time positive C13-urea breath test (C13-UBT) between 2007 to 2014, who underwent a second C13-UBT after receiving clarithromycin-based triple therapy. Data regarding age, gender, socioeconomic status (SES), smoking (current smokers or "never smoked"), and drug use were extracted from the Clalit health maintenance organization database. RESULTS: Out of 120,914 subjects with a positive first time C13-UBT, 50,836 (42.0%) underwent a second C13-UBT test. After excluding former smokers, 48,130 remained who were eligible for analysis. The mean age was 44.3±18.2years, 69.2% were females, 87.8% were Jewish and 12.2% Arabs, 25.5% were current smokers. The overall eradication failure rates were 33.3%: 34.8% in current smokers and 32.8% in subjects who never smoked. In a multivariate analysis, eradication failure was positively associated with current smoking (Odds Ratio {OR} 1.15, 95% CI 1.10-1.20, p<0.001), female gender (OR 1.20, 95% CI 1.14-1.25, p<0.001) and a low socioeconomic status (OR 1.24, 95% CI 1.17-1.31, p<0.001). CONCLUSIONS: After controlling for socio-demographic confounders, smoking was found to significantly increase the likelihood of unsuccessful first-line treatment for H. pylori infection.
BACKGROUND AND AIMS: Data regarding the impact of smoking on the success of Helicobacter pylori (H. pylori) eradication are conflicting, partially due to the fact that sociodemographic status is associated with both smoking and H. pylori treatment success. We aimed to assess the effect of smoking on H. pylori eradication rates after controlling for sociodemographic confounders. METHODS: Included were subjects aged 15 years or older, with a first time positive C13-urea breath test (C13-UBT) between 2007 to 2014, who underwent a second C13-UBT after receiving clarithromycin-based triple therapy. Data regarding age, gender, socioeconomic status (SES), smoking (current smokers or "never smoked"), and drug use were extracted from the Clalit health maintenance organization database. RESULTS: Out of 120,914 subjects with a positive first time C13-UBT, 50,836 (42.0%) underwent a second C13-UBT test. After excluding former smokers, 48,130 remained who were eligible for analysis. The mean age was 44.3±18.2years, 69.2% were females, 87.8% were Jewish and 12.2% Arabs, 25.5% were current smokers. The overall eradication failure rates were 33.3%: 34.8% in current smokers and 32.8% in subjects who never smoked. In a multivariate analysis, eradication failure was positively associated with current smoking (Odds Ratio {OR} 1.15, 95% CI 1.10-1.20, p<0.001), female gender (OR 1.20, 95% CI 1.14-1.25, p<0.001) and a low socioeconomic status (OR 1.24, 95% CI 1.17-1.31, p<0.001). CONCLUSIONS: After controlling for socio-demographic confounders, smoking was found to significantly increase the likelihood of unsuccessful first-line treatment for H. pyloriinfection.
Authors: Sabrina H Tsang; M Larissa Avilés-Santa; Christian C Abnet; Maximo O Brito; Martha L Daviglus; Sylvia Wassertheil-Smoller; Sheila F Castañeda; Sharon Minnerath; Gregory A Talavera; Barry I Graubard; Bharat Thyagarajan; M Constanza Camargo Journal: Clin Gastroenterol Hepatol Date: 2021-03-02 Impact factor: 11.382
Authors: Jeemyoung Kim; Eun Jeong Gong; Myeongsook Seo; Hyun Il Seo; Jong Kyu Park; Sang Jin Lee; Koon Hee Han; Woo Jin Jeong; Young Don Kim; Gab Jin Cheon Journal: J Pers Med Date: 2022-01-06
Authors: Juanita Ann Spiteri; Graziella Zahra; John Schembri; Anthea Pisani; Elaine Borg; Neville Spiteri; Eliezer Zahra Bianco; Paul Caruana; James Gauci; Martina Muscat; Christopher Barbara; Pierre Ellul Journal: Ann Gastroenterol Date: 2021-04-02